Efficacy and safety of IL-23 inhibitors in the treatment of moderate to severe UC

The meta-analysis conducted on randomized controlled trials provides comprehensive insights into the efficacy and safety of IL-23 inhibitors for the treatment of moderate to severe ulcerative colitis (UC). Below is a detailed summary of the findings:

### Efficacy of IL-23 Inhibitors

1. **Central Role of IL-23 in UC Pathogenesis**:

• IL-23 is a critical driver of immune-mediated intestinal inflammation in UC via activation of the Th17 pathway, making it a promising therapeutic target.

2. **Agents Evaluated**:

• The analysis assessed three primary IL-23p19 inhibitors: **Mirikizumab**, **Guselkumab**, and **Risankizumab**.

3. **Induction Phase Effectiveness**:

• IL-23 inhibitors consistently demonstrated strong efficacy during the induction phase of treatment, rapidly reducing disease activity.

4. **Clinical Remission**:

• Patients treated with IL-23 inhibitors were more likely to achieve clinical remission, characterized by symptom control and resolution of inflammation.

5. **Clinical Response**:

• Significant improvements were observed in disease symptoms, including reductions in abdominal pain, diarrhea, and rectal bleeding.

6. **Endoscopic Healing**:

• IL-23 inhibitors were associated with improved mucosal appearance on endoscopy, indicative of reduced inflammation and healing.

7. **Histologic Improvement**:

• Treatment benefits extended beyond symptom relief to microscopic mucosal healing, emphasizing the profound anti-inflammatory effects of IL-23 inhibition.

8. **Effectiveness in Biologic-Naïve Patients**:

• IL-23 inhibitors demonstrated robust efficacy in patients who had not previously received biologic therapy, making them an excellent option for first-line advanced therapy.

9. **Utility in Refractory Disease**:

• Patients with prior inadequate response or intolerance to biologics or JAK inhibitors also experienced meaningful clinical benefits, highlighting their utility in difficult-to-treat cases.

10. **Consistency Across Patient Subgroups**:

• Treatment efficacy was stable across diverse patient histories, disease severities, and backgrounds, demonstrating the broad applicability of IL-23 inhibitors.

### Safety of IL-23 Inhibitors

1. **Favorable Safety Profile**:

• IL-23 inhibitors were generally well tolerated, with no significant increase in overall safety concerns.

2. **Low Risk of Serious Infections**:

• Selective IL-23 blockade did not show a heightened risk of serious infections, a common concern with immunosuppressive therapies.

3. **Reduced Treatment Discontinuation**:

• Patients receiving IL-23 inhibitors were less likely to discontinue therapy due to adverse events, suggesting high tolerability.

4. **Mechanistic Advantage**:

• By selectively targeting IL-23p19 and sparing IL-12–related immune functions, IL-23 inhibitors preserve interferon signaling, potentially reducing systemic immunosuppression and associated risks.

### Position in Treatment Algorithms

• **Advanced Therapy Option**:
• IL-23 inhibitors represent an important addition to the therapeutic armamentarium for moderate to severe UC, offering a targeted and effective anti-inflammatory approach.

• **Personalization and Future Research**:
• While IL-23 inhibitors show promise, further head-to-head trials and long-term real-world studies are needed to refine their positioning in treatment algorithms and optimize their use in personalized care.

### Conclusion

IL-23 inhibitors, including Mirikizumab, Guselkumab, and Risankizumab, are highly effective and well-tolerated treatments for moderate to severe UC. Their ability to induce clinical remission, improve endoscopic and histologic outcomes, and benefit both biologic-naïve and refractory patients underscores their therapeutic value. The favorable safety profile, combined with mechanistic advantages, positions IL-23 inhibitors as a vital option in the management of UC, with promising potential for further advancements through ongoing research.